CN114712424A - 一种具有解酒保肝作用的中药制剂及其制备方法和应用 - Google Patents
一种具有解酒保肝作用的中药制剂及其制备方法和应用 Download PDFInfo
- Publication number
- CN114712424A CN114712424A CN202210515120.XA CN202210515120A CN114712424A CN 114712424 A CN114712424 A CN 114712424A CN 202210515120 A CN202210515120 A CN 202210515120A CN 114712424 A CN114712424 A CN 114712424A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- preparation
- chinese medicine
- traditional chinese
- effects
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 73
- 230000000694 effects Effects 0.000 title claims abstract description 52
- 239000003814 drug Substances 0.000 title claims abstract description 50
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract description 46
- 210000004185 liver Anatomy 0.000 title claims abstract description 39
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 76
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 70
- 229930003451 Vitamin B1 Natural products 0.000 claims abstract description 40
- 229960003495 thiamine Drugs 0.000 claims abstract description 40
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract description 40
- 235000010374 vitamin B1 Nutrition 0.000 claims abstract description 40
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 39
- 229960003080 taurine Drugs 0.000 claims abstract description 38
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 35
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 35
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 35
- 239000011718 vitamin C Substances 0.000 claims abstract description 35
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims abstract description 29
- 235000010241 potassium sorbate Nutrition 0.000 claims abstract description 29
- 239000004302 potassium sorbate Substances 0.000 claims abstract description 29
- 229940069338 potassium sorbate Drugs 0.000 claims abstract description 29
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 27
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 26
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 25
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 25
- 208000007848 Alcoholism Diseases 0.000 claims abstract description 24
- 235000008584 Hovenia dulcis Nutrition 0.000 claims abstract description 24
- 244000010000 Hovenia dulcis Species 0.000 claims abstract description 24
- 201000007930 alcohol dependence Diseases 0.000 claims abstract description 24
- 235000001188 Peltandra virginica Nutrition 0.000 claims abstract description 22
- 235000012907 honey Nutrition 0.000 claims abstract description 22
- 239000008213 purified water Substances 0.000 claims abstract description 19
- 244000248825 Peltandra virginica Species 0.000 claims abstract 6
- 239000000706 filtrate Substances 0.000 claims description 22
- 238000001914 filtration Methods 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- 210000000582 semen Anatomy 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 8
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 7
- 230000001376 precipitating effect Effects 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 6
- 238000005119 centrifugation Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 3
- 208000005584 Alcoholic Intoxication Diseases 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims 2
- 206010067125 Liver injury Diseases 0.000 abstract description 11
- 231100000753 hepatic injury Toxicity 0.000 abstract description 9
- 239000000126 substance Substances 0.000 abstract description 9
- 230000035922 thirst Effects 0.000 abstract description 6
- 238000010791 quenching Methods 0.000 abstract description 5
- 230000000171 quenching effect Effects 0.000 abstract description 4
- 244000197580 Poria cocos Species 0.000 description 21
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 19
- 230000001737 promoting effect Effects 0.000 description 15
- 230000006870 function Effects 0.000 description 13
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 12
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 11
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 11
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 229940118019 malondialdehyde Drugs 0.000 description 9
- 230000035622 drinking Effects 0.000 description 8
- 229960003180 glutathione Drugs 0.000 description 8
- 210000005228 liver tissue Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 235000014787 Vitis vinifera Nutrition 0.000 description 7
- 240000006365 Vitis vinifera Species 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 150000004676 glycans Chemical class 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 239000005017 polysaccharide Substances 0.000 description 7
- 229920001282 polysaccharide Polymers 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 206010047700 Vomiting Diseases 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000000691 measurement method Methods 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000014101 wine Nutrition 0.000 description 4
- 208000004930 Fatty Liver Diseases 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 206010038743 Restlessness Diseases 0.000 description 3
- 230000002075 anti-alcohol Effects 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 210000001156 gastric mucosa Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 206010036067 polydipsia Diseases 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 230000002936 tranquilizing effect Effects 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 2
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 2
- 208000035240 Disease Resistance Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 231100000439 acute liver injury Toxicity 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 210000000013 bile duct Anatomy 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 235000007240 daidzein Nutrition 0.000 description 2
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 201000003152 motion sickness Diseases 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- -1 puerarin glycoside Chemical class 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 230000007863 steatosis Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- QZMAEZWZCGBZFK-AOJWCAIYSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4ar,6ar,6bs,8as,12as,14ar,14br)-4,4,6a,6b,11,11,14b-heptamethyl-8a-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,5-dihydroxy-4-[(2s,3r Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C(O)=O)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O QZMAEZWZCGBZFK-AOJWCAIYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QZMAEZWZCGBZFK-UHFFFAOYSA-N 28-(beta-D-Glucopyranosyloxy)-28-oxoolean-12-en-3beta-yl 3-O-(beta-D-glucopyranosyl)-beta-D-glucopyranosiduronic acid Natural products C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(CO)O2)O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC(C1O)OC(C(O)=O)C(O)C1OC1OC(CO)C(O)C(O)C1O QZMAEZWZCGBZFK-UHFFFAOYSA-N 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010017815 Gastric perforation Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FHNINJWBTRXEBC-UHFFFAOYSA-N Sudan III Chemical compound OC1=CC=C2C=CC=CC2=C1N=NC(C=C1)=CC=C1N=NC1=CC=CC=C1 FHNINJWBTRXEBC-UHFFFAOYSA-N 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000210 effect on cough Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000019249 food preservative Nutrition 0.000 description 1
- 239000005452 food preservative Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- KPJWZUAARPJYSB-UHFFFAOYSA-N glycoside C Natural products CC1(C)OC(=O)C23CCC1C2(O)CCC(C1(CCC24)C)(C)C3CCC1C2(C)CCCC4(C)COC(C(C(O)C1O)OC2C(C(O)C(CO)O2)O)OC1COC1OC(CO)C(O)C(O)C1O KPJWZUAARPJYSB-UHFFFAOYSA-N 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000012674 herbal formulation Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019988 mead Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000005554 pickling Methods 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 235000021018 plums Nutrition 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 235000021085 polyunsaturated fats Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940099373 sudan iii Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明属于中药制剂技术领域，涉及一种具有解酒保肝作用的中药制剂及其制备方法，中药制剂由葛根、茯苓、枳椇子、牛磺酸、维生素C、维生素B1、蜂蜜、青梅汁、山梨酸钾和纯化水制备而成；每1000ml中药制剂中，葛根、茯苓、枳椇子、牛磺酸、维生素C、维生素B1、蜂蜜、浓缩青梅汁和山梨酸钾用量比依次为33～48g：35～44g：20～26g：0.5～2g：0.5～2g：0.01～0.05g：95～120g：40～60ml：0.2～0.75g，余量为纯化水。本发明提供的中药制剂具有解酒、解渴、消除疲劳的功效，能对化学性肝损伤起到辅助保护作用，适用人群广。
Description
技术领域
本发明属于中药制剂技术领域，涉及一种具有解酒保肝作用的中药制剂及其制备方法和应用。
背景技术
酒是人们生活中常见的饮品，少量饮酒对身体有一定的好处，但是饮酒不当却会对身体造成许多危害，例如：损伤肝脏和肠胃，导致代谢紊乱、对大脑造成伤害，导致记忆力下降，大脑功能衰退。尤其是由酒精引起的化学性肝损伤，当酒精进入人体后，90％都要经过肝脏进行分解代谢，乙醇进入肝细胞后氧化为乙醛，乙醛会使肝细胞发生脂肪变性、坏死，继而导致肝功能异常，影响到肝脏的健康，因此过量的喝酒，大量的酒精摄入，肝脏就需要超负荷分解酒精，分解的酒精过程中产生的代谢产物乙醛，乙醛协同乙醇会影响肝内脂肪的转化和分解，导致脂肪在肝脏内蓄积，如果肝内脂肪过量形成脂肪肝也就是酒精性脂肪肝。乙醛还会破坏毛细胆管细胞和胆管上皮细胞，每日都超量饮酒、反复循环、得不到及时修复，长此以往会导致酒精性肝损伤；此外，酒精是有刺激性的物质，大量的酒精会破坏我们的胃粘膜，胃粘膜上一成含有蛋白质和激素的粘液，有保护肠胃的作用，胃粘膜被破坏，胃表层直接与酒精接触，引起一系列的肠胃问题，过量的酒精刺激，严重的情况甚至会造成胃穿孔。
因此，经常饮酒的人群，需要采取手段来解酒，现有的解酒方法可谓是五花八门，解酒药物也是比比皆是。但是这些解酒的药物存在以下缺陷，口感味道较难接受，有些虽然能起到解酒，但是不能对化学性肝损伤起到保护作用，功能单一，不能适用于不同解酒症状的人群；随着技术发展，有些药物能对肝脏起到保护作用，但效果不佳，或是有一定的毒副作用。
发明内容
针对现有解酒药物存在的技术问题，本发明提供一种具有解酒保肝作用的中药制剂及其制备方法，具有解酒、解渴、消除疲劳的功效，能对化学性肝损伤起到辅助保护作用，适用人群广。
为了实现上述目的，本发明采用的技术方案是：
一种具有解酒保肝作用的中药制剂，所述中药制剂由葛根、茯苓、枳椇子、牛磺酸、维生素C、维生素B1、蜂蜜、青梅汁、山梨酸钾和纯化水制备而成；所述每1000ml中药制剂中，葛根、茯苓、枳椇子、牛磺酸、维生素C、维生素B1、蜂蜜、浓缩青梅汁和山梨酸钾用量比依次为33～48g：35～44g：20～26g：0.5～2g：0.5～2g：0.01～0.05g：95～120g：40～60ml：0.2～0.75g，余量为纯化水。
进一步的，所述每1000ml中药制剂中，葛根、茯苓、枳椇子、牛磺酸、维生素C、维生素B1、蜂蜜、浓缩青梅汁和山梨酸钾用量比依次为40g：40g：22.5g：1g：1g：0.025g：100g：50ml：0.5g。
一种所述的具有解酒保肝作用的中药制剂的制备方法，包括以下步骤：
1)按照权利要求2所述的用量准备葛根、茯苓、枳椇子、牛磺酸、维生素C、维生素B1、蜂蜜、浓缩青梅汁、山梨酸钾、纯化水；
2)取葛根、茯苓和枳椇子，经过煎煮和过滤，得到滤液；
3)对上述滤液经减压浓缩至相对密度1.05-1.15，再经醇沉、过滤，沉淀为稠膏状物质；
4)向稠膏状物质中，分别加入牛磺酸、维生素C、维生素B1、蜂蜜、浓缩青梅汁、山梨酸钾以及纯化水，搅拌混匀得到混合液，经离心后，过滤，取上清液即为中药制剂。
进一步的，所述步骤2)的具体过程是：
2.1)将葛根、茯苓和枳椇子混合得到混合物，按照混合物质量的10倍用量向混合物中加水，浸泡2小时，煎煮2小时，过滤，得到初级滤渣和初级滤液；
2.2)向初级滤渣中继续加水，水的加入量是三种混合物总质量的8倍，浸泡2小时，煎煮2小时，过滤，得到次级滤渣和次级滤液；
2.3)将步骤2.1)和初级滤液步骤2.2)的次级滤液混合，得到滤液。
进一步的，所述步骤3)中，减压浓缩的条件是：温度60℃，真空度-0.06～-0.08Mpa。
进一步的，所述步骤3)中，采用60％乙醇进行醇沉，醇沉时间为24小时以上。
进一步的，所述步骤4)中，搅拌时间为30min，搅拌速度1000r/min，离心速度3000r/min，离心时间30min。
一种所述的制备方法制备的中药制剂在制备解酒护肝药物中的应用。
本发明的有益效果是：
1、本发明提供一种具有解酒保肝作用的中药制剂，由葛根、茯苓、枳椇子、牛磺酸、维生素C、维生素B1、蜂蜜、青梅汁、山梨酸钾和纯化水制备而成。且以葛根、茯苓、枳椇子、牛磺酸、维生素C、维生素B1为主料，以蜂蜜、青梅汁、山梨酸钾和纯化水为辅料。葛根具有清热、降火、排毒的功效；茯苓具有利水渗湿、健脾、安神的功效，枳椇子具有清热利尿，止咳除烦，解酒毒的功效；牛磺酸具有抗炎、解热、利胆、强肝、解毒、消除疲劳等作用，维生素C具备抗氧化，抗自由基的功效，能有效预防病毒、细菌感染，预防癌症的作用，维生素B1具有在体内分解酒精的作用，蜂蜜具有增强肝脏的解毒功能，养肝护肤的作用，青梅汁具有生津解渴、刺激食欲、消除疲劳、助消化、通肠胃的功效，各个原料协同作用，发挥中药的作用功效，具有很好的解酒护肝作用；同时能安神助眠，保护肠道，缓解疲劳的作用。
2、本发明提供的中药制剂，采用中药制成，安全无毒，且选择的中药性平、味甘，制成的中药制剂口味佳，让人容易接受饮用，适用于人群较广。
具体实施方式
现结合实施例对本发明做详细的说明。
本发明提供一种具有解酒保肝作用的中药制剂，中药制剂由葛根、茯苓、枳椇子、牛磺酸、维生素C、维生素B1、蜂蜜、青梅汁、山梨酸钾和纯化水制备而成。且葛根、茯苓、枳椇子、牛磺酸、维生素C、维生素B1为主料，蜂蜜、青梅汁、山梨酸钾和纯化水为辅料。各个原料的功效如下。
葛根：性凉、气平、味甘，具有清热、降火、排毒诸功效；清风寒，净表邪，解肌热，止烦渴。葛根含异黄酮成分葛根素、葛根素木糖甙、大豆黄酮、大豆黄酮甙及β-谷甾醇、花生酸，主要活性成分为大豆素(daidzein)、大豆甙(daidzin)、葛根素(puerarin)、葛根素-7-木糖甙；葛根中的异黄酮类化合物葛根素对高血压、高血脂、高血糖和心脑血管疾病有一定疗效。具有营养心肌、解肌发表、降糖降脂和益智的功效。
茯苓：性平，味甘淡，归心、肺、脾、肾经，是我国传统药材中非常重要的健脾利湿中药材，具有利水渗湿、健脾、安神的功效。茯苓气味淡而渗，其性上行，生津液，开腠理，滋水源而下降，利小便，故张洁古谓其属阳，浮而升，言其性也；能利窍去湿，利窍则开心益智，导浊生津；去湿则逐水燥脾，补中健胃；袪惊痫，厚肠脏，治痰之本，助药之降；茯苓含蛋白质、卵磷脂、胆碱、茯苓多糖等有效成分，能够增强机体组织的生理活性，促进人体免疫系统功能。
枳椇子：味甘，性平。清热利尿，止咳除烦，解酒毒。用于热病烦渴，呃逆，呕吐，小便不利，酒精中毒。具有安神、加速肠道蠕动，中枢抑制作用，给人体补充养分，增强机体的抗病能力。枳椇子中含有大量的葡萄糖、有机酸，既能扩充人体的血容量，又能解酒毒，故有醒酒安神的作用；枳椇子含有大量水分、葡萄糖、有机盐、脂类物质，具有促进尿液排泄，加速肠道蠕动等作用，故能通利二便；枳椇子中含有大量的钙和枳椇子皂甙，具有中枢抑制作用，能够抗惊厥，防止手足抽搐痉挛，可用来治疗风湿痹痛麻木之症；枳椇子中含有大量的葡萄糖、蔗糖、果糖、有机酸、无机盐、维生素等，能生津止渴，清热除烦，并能给人体补充养分，增强机体的抗病能力；近年来研究发现，枳椇子中含有麦草碱、B-咔啉、枳椇甙C、D、G、H、鼠李碱等，具有抗脂质过氧化和降低血压等作用。
牛磺酸：通常被称为一种氨基酸，它既不是人体蛋白结构一部分，也不是一种必需氨基酸。它与甘氨酸和γ氨基丁酸产生化学反应，作为组织和血液的神经抑制剂传递者。它是一种氨基酸类化合物，人的心脏，骨骼肌和神经系统含有大量这种元素，在胆汁中也可以发现牛磺酸，它的作用是促进肠道消化，并作为膳食脂肪的乳化剂。牛磺酸具有增强心肌收缩、促进婴儿大脑发育、对抗焦虑情绪、提高学习能力、提高视觉功能、促进脂肪代谢、促进降低血糖、抑制白内障发生以及产生能量消除疲劳的作用，有抗炎、解热、镇痛、镇静、降血压、降血糖、抗心律失常、利胆、强肝、解毒等作用。维生素C：是一种存在于食物中的维他命，可作为营养补充品，维持免疫功能，保持血管完整，促进非血红素铁吸收等所必需，还具备抗氧化，抗自由基的功效，能有效预防病毒、细菌感染，预防癌症、中风、心血管疾病的发生，能促进微量元素吸收、改善心肌功能、帮助伤口愈合、预防黑色素沉着等等。
维生素B1：是维生素家族中的一员，其主要作用是参与到身体内辅酶的合成与代谢，能维持正常糖代谢的作用，在体内分解酒精，因此维生素B1可促进神经系统脑细胞的正常发育和工作，促进大脑的生长和发育；维生素B1可缓解疲劳，改善神经疲劳，改善休息和睡眠质量；维生素B1还可有助于消化，它可促进体内消化的功能，增加胃肠蠕动；维生素B1还有助于减轻晕车、晕船的症状。
蜂蜜：性平，味甘，具有补虚润燥、润肺通肠、解毒止痛之功效。对咳嗽、支气管炎疗效显著，可预防和治疗便秘。它具有较强的抗氧化作用，能够帮助人提升皮肤、身体机能，蜂蜜能增强肝脏的解毒功能，养肝护肤；蜂蜜能促进组织再生，加速伤口愈合，并使肉芽组织健康成长。
青梅汁：是将青梅通过粗盐(或海盐)腌制后，所产生的汁液。具有生津解渴、刺激食欲、消除疲劳等功效，对咽干、咽痛、声嘶均有疗效，可以解除疲劳，可以助消化、通肠胃，通经活络、消炎化瘀等。
山梨酸钾：山梨酸钾是山梨酸的钾盐，山梨酸是一种多不饱和脂肪，山梨酸钾是白色盐，非常易溶于水，因为它的抗微生物特性阻止了有害细菌和霉菌的生长和传播，可用作食品防腐剂，可以延长食品的保质期。
进一步的，本发明提供的具有解酒保肝作用的中药制剂由葛根、茯苓、枳椇子、牛磺酸、维生素C、维生素B1、蜂蜜、青梅汁、山梨酸钾和纯化水制备而成；每1000ml中药制剂中，葛根、茯苓、枳椇子、牛磺酸、维生素C、维生素B1、蜂蜜、浓缩青梅汁和山梨酸钾用量比依次为33～48g：35～44g：20～26g：0.5～2g：0.5～2g：0.01～0.05g：95～120g：40～60ml：0.2～0.75g，余量为纯化水。
优选的，每1000ml中药制剂中，葛根、茯苓、枳椇子、牛磺酸、维生素C、维生素B1、蜂蜜、浓缩青梅汁和山梨酸钾用量比依次为40g：40g：22.5g：1g：1g：0.025g：100g：50ml：0.5g。
进一步的，以具体的实施例说明本发明提供的中药制剂的具体组分以及功效。
实施例1～实施例5
实施例1～实施例5提供的中药制剂均由葛根、茯苓、枳椇子、牛磺酸、维生素C、维生素B1、蜂蜜、青梅汁、山梨酸钾和纯化水制备而成。各实施例中，每1000ml的中药制剂中，各个物料的用量参见表1。
表1实施例1～实施例5提供的中药制剂的用量
实施例6
以实施例1的用量比为例，说明本实施例提供的具有解酒保肝作用的中药制剂的制备方法。
本实施例提供的制备方法包括以下步骤：
1)按照实施例1提供的用量准备33g葛根、35g茯苓、20g枳椇子、0.5g牛磺酸、0.5g维生素C、0.01g维生素B1、95g蜂蜜、40ml浓缩青梅汁和0.2g山梨酸钾，余量为纯化水。
2)将33g葛根、35g茯苓和20g枳椇子，经过煎煮和过滤，得到滤液。
本实施例步骤2)的具体过程是：
2.1)将33g葛根、35g茯苓和20g枳椇子混合，然后加水，水的加入量是葛根、茯苓和枳椇子三者总质量的10倍，即水880g，浸泡2小时，煎煮2小时，过滤，得到初级滤渣和初级滤液；
2.2)向上述初级滤渣中继续加水，水的加入量是葛根、茯苓和枳椇子三者总质量的8倍，加入水704g，浸泡2小时，煎煮2小时，过滤，得到次级滤渣和次级滤液；
2.3)将步骤2.1)和初级滤液步骤2.2)的次级滤液混合，得到滤液。
3)对上述滤液经减压浓缩至相对密度1.05-1.15，再经醇沉、过滤，沉淀为稠膏状物质。
减压浓缩的条件是：温度60℃，真空度-0.06～-0.08Mpa，相对密度指的是相对于水的密度；用60％乙醇进行醇沉24小时以上，过滤，滤液减压浓缩回收乙醇，得稠膏状物质。
4)向稠膏状物质中，分别加入0.5g牛磺酸、0.5g维生素C、0.01g维生素B1、95g蜂蜜、40ml浓缩青梅汁、0.2g山梨酸钾以及余量的纯化水，搅拌30min，搅拌速度1000r/min，离心速度3000r/min，离心时间30min，过滤，取上清液即为中药制剂，中药制剂为1000ml。
实施例7～实施例10
分别按照实施例2-实施例5的用量比，并采用实施例6相同的方法步骤，对应制备得到四组中药制剂。
下面通过几组典型案例，说明本发明提供的中药制剂具有很好的解酒作用。
1、陈某，女，销售人员。因工作应酬经常喝酒，酒后常感恶心呕吐、头疼胸闷，食欲不振、乏力、发现肝功异常，经检查为精度酒精性肝病。后服上述5组中药制剂中的随机一组，共三个疗程，一个疗程为7天，每天早晚各一次，每次50ml，发现有明显好转，无恶心呕吐、头疼消失、胸闷也不发生、食欲增加、身体有劲、肝功恢复正常。
2、王某某，男，公司中层管理者，喝酒后出现恶心、呕吐，然后2～3天内都觉得干渴、困倦、精神不集中、工作频繁出错。在酒前服用上述5组中随机一组中药制剂100ml，发现酒后恶心、呕吐、干渴症状消失，隔天上班就觉得精神集中，不会犯困。
3、焦某某，男，某行政部门主管。喝酒后出现耍酒疯，一晚上不睡觉，说胡话。在酒后服用上述5组中随机一组中药制剂100ml，1～2小时能安静下来，进入睡眠状态。
进一步的，通过下述实验对中药制剂的功效性能进行验证分析。
试验1
实验组：实施例6-实施例10制备的中药制剂
取上述5组不同含量的中药制剂，经品尝后发现5组中药制剂均是味道带甜、易接受。进一步测定其功效成分，具体为葛根素、维生素C、牛磺酸和维生素B1的含量。测量方法为标准测量方法。检测结果参见表2。
表2实施例6-实施例10制备的中药制剂的功效成分
| 项目 | 实施例6 | 实施例7 | 实施例8 | 实施例9 | 实施例10 |
| 葛根素(mg/100ml) | 74.2 | 75.9 | 76.7 | 76.8 | 77.1 |
| 维生素C(mg/100ml) | 70 | 89 | 136 | 172 | 210 |
| 牛磺酸(mg/100ml) | 48.3 | 77.5 | 99.2 | 130 | 178 |
| 维生素B1(mg/100ml) | 0.97 | 1.86 | 2.1 | 3.2 | 4.0 |
由表2可知，当各原料的用量增加，葛根素含量、维生素C含量、牛磺酸含量和维生素B1含量均呈上升趋势，但是当各原料的用量大于实施例3的用量时，葛根素含量、维生素C含量、牛磺酸含量和维生素B1含量增加幅度较为平缓。因此综合考虑，实施例8制备出的中药制剂中各原料的用量为较佳选择，即实施例3的用量比为优选用量比。
试验2
试验组：实施例3提供的用量
对比组1：40g葛根
对比组2：1g维生素C
对比组3：1g牛磺酸
对比组4：0.025g维生素B1
对比组5：葛根、茯苓、枳椇子、牛磺酸、维生素C、维生素B1，用量与实施例3相同
选取上述实验组和各对比组的用量，按照实施例6的制备方法制备成1000ml中药制剂，然后测定各组中药制剂中的葛根素、维生素C、牛磺酸和维生素B1的含量。测量方法为标准测量方法。检测结果参见表3。
表3实施例和对比组制备的中药制剂的功效成分
| 项目 | 试验组 | 对比组1 | 对比组2 | 对比组3 | 对比组4 | 对比组5 |
| 葛根素(mg/100ml) | 76.7 | 75.5 | — | — | — | 76.04 |
| 牛磺酸(mg/100ml) | 99.2 | — | — | 98.6 | — | 98.92 |
| 维生素C(mg/100ml) | 138 | — | 130 | — | — | 133 |
| 维生素B1(mg/100ml) | 2.16 | — | — | — | 2.01 | 2.07 |
从表3可知，与纯物质相比，当葛根、茯苓、枳椇子、牛磺酸、维生素C和维生素B1混合后，几种药物协同作用，能提升葛根素、牛磺酸、维生素C和维生素B1的含量。
进一步向组合物中加入蜂蜜、青梅汁和山梨酸钾辅料形成制剂，制剂中的葛根素、牛磺酸、维生素C和维生素B1含量也能得到提升。说明主料和辅料能够相互协同，促进原料活性成分的提升。
由此可见，当本发明的药物配伍后，能发挥原料之间的协同作用，促进葛根、牛磺酸、维生素C和维生素B1的功效提升，本发明制剂具有很好的解酒效果，改善心肌的氧代谢，对心肌代谢产生有益作用，同时能扩张血管，改善微循环，降低血管阻力，起到护肝作用。
试验3
取实施例8制备的中药制剂，放置3个月，中药制剂中粗多糖和山梨酸钾的稳定性。放置条件为：温度35～39℃，相对湿度为70％～80％，每个月检测一次，检测方法为现有的标准方法，结果参见表4。
表4中药制剂中粗多糖和山梨酸钾的稳定性结果
| 检验项目 | 计量单位 | 0 | 1 | 2 | 3 |
| 粗多糖(以葡萄糖计) | g/100mL | 0.061 | 0.15 | 0.14 | 0.14 |
| 山梨酸钾(以山梨酸计) | g/L | 0.411 | 0.411 | 0.410 | 0.412 |
从表4可知，所检指标符合规定要求，且放置一个月后，粗多糖提升2.3倍，继续放置粗多糖含量维持稳定；而山梨酸钾含量从放置开始基本维持稳定。
试验4
1、样品及剂量
实施例3提供的用量以及实施例8制备的中药制剂。人口服推荐剂量为每日100ml，因推荐量较大，实验前，取成品原液10L用旋转蒸发仪浓缩至4L，成为2.5倍浓缩液，成人体重按60kg计算，折合2.5倍浓缩液推荐剂量为0.667ml/kg·bw。
2、实验动物及环境
SPF级ICR种雄性小鼠50只，体重18g～22g，实验环境为屏障环境，温度为22℃～26℃，湿度52％～56％。
3、剂量选择与受试物给予方式
设中药制剂2.5倍浓缩液三个剂量组分别为3.33ml/kg·bw，6.67ml/kg·bw和20.00ml/kg·bw(分别相当于人体推荐剂量的5，10，30倍)，同时设空白对照组和肝损伤模型对照组。
低、中剂量受试液配制时，分别取中药制剂2.5倍浓缩液33.3ml,66.7ml加蒸馏水至200ml，高剂量组给予2.5倍浓缩液；空白对照组和肝损伤模型对照组给予等体积蒸馏水，每天给小鼠灌胃1次，连续30天，灌胃体积为0.2ml/10g·bw。
4、试验方法
(1)动物处理
各剂量组按上述剂量设计灌胃给予受试液，空白对照组、模型对照组灌胃给予等体积溶剂，每日1次，连续30天。第30天各剂量组和模型对照组灌胃给予50％乙醇(12ml/kg.bw)，造成急性肝损伤模型，空白对照组灌胃给予蒸馏水，禁食16小时处死动物，进行各项指标检测及病理组织学检查。
(2)指标检测
取肝脏用生理盐水制成10％的肝匀浆，检测肝组织中还原型谷胱甘肽(GSH)、甘油三酯(TG)、丙二醛(MDA)含量。肝组织内GSH、MDA含量按南京建成生物工程研究所提供的测试盒说明书进行，肝组织内TG含量用BECKMAN COULTER AU680全自动生化分析仪测定。结果参见表5。
表5样品对小鼠肝组织内MDA、GSH和TG的影响
由表5可见，模型对照组的MDA，TG均高于空白对照组，模型对照组的GSH低于空白对照组，差异均有显著性(P<0.05)。高剂量组的TG明显低于模型对照组，高剂量组GSH明显高于模型对照组，差异有显著性(P<0.05)。
(3)病理组织学检查
从小鼠肝左叶中部做横切面取材，冰冻切片，苏丹Ⅲ染色。镜检时从肝脏的一端视野开始记录细胞的病理变化，用40倍物镜连续观察整个组织切片，观察脂滴在肝脏的分布、范围和面积。
并按照按以下标准进行评分，结果参见表6。
0分—肝细胞内脂滴散在、稀少。
1分—含脂滴的肝细胞不超过1/4。
2分—含脂滴的肝细胞不超过1/2。
3分—含脂滴的肝细胞不超过3/4。
4分—肝组织几乎被脂滴代替。
表6样品对小鼠肝脏组织脂肪变性的程度的影响
由表6可见，模型对照组肝脏脂肪变性的程度高于空白对照组，差异有显著性(P<0.05)；高剂量组肝脏脂肪变性的程度明显低于模型对照组，差异有显著性(P<0.05)。
由于肝组织中丙二醛(MDA)、还原型谷胱甘肽(GSH)、甘油三酯(TG)三项检测指标结果阳性，或肝组织中丙二醛(MDA)、还原型谷胱甘肽(GSH)、甘油三酯(TG)三项指标中任两项指标阳性和病理检测结果阳性，可判定受试样品对化学性肝损伤具有辅助保护功能。
以本发明提供的中药制剂给小鼠经口灌胃30天后，以乙醇造成急性肝损伤模型。高剂量组动物的肝脏TG明显低于模型对照组，肝脏GSH明显高于模型对照组，肝脏脂肪变性程度明显低于模型对照组，差异具有显著性(P<0.05)，说明本发明提供的中药制剂对化学性肝损伤具有辅助保护功能，可用来制备解酒护肝药物。
Claims (8)
1.一种具有解酒保肝作用的中药制剂，其特征在于，所述中药制剂由葛根、茯苓、枳椇子、牛磺酸、维生素C、维生素B1、蜂蜜、青梅汁、山梨酸钾和纯化水制备而成；所述每1000ml中药制剂中，葛根、茯苓、枳椇子、牛磺酸、维生素C、维生素B1、蜂蜜、浓缩青梅汁和山梨酸钾用量比依次为33～48g：35～44g：20～26g：0.5～2g：0.5～2g：0.01～0.05g：95～120g：40～60ml：0.2～0.75g，余量为纯化水。
2.根据权利要求1所述的具有解酒保肝作用的中药制剂，其特征在于，所述每1000ml中药制剂中，葛根、茯苓、枳椇子、牛磺酸、维生素C、维生素B1、蜂蜜、浓缩青梅汁和山梨酸钾用量比依次为40g：40g：22.5g：1g：1g：0.025g：100g：50ml：0.5g。
3.一种如权利要求1或2所述的具有解酒保肝作用的中药制剂的制备方法，其特征在于，所述制备方法包括以下步骤：
1)按照权利要求1或2所述的用量比准备葛根、茯苓、枳椇子、牛磺酸、维生素C、维生素B1、蜂蜜、浓缩青梅汁、山梨酸钾、纯化水；
2)取葛根、茯苓和枳椇子，经过煎煮和过滤，得到滤液；
3)对上述滤液经减压浓缩至相对密度1.05-1.15，再经醇沉、过滤，沉淀为稠膏状物质；
4)向稠膏状物质中，依次加入牛磺酸、维生素C、维生素B1、蜂蜜、浓缩青梅汁、山梨酸钾以及纯化水，搅拌混匀得到混合液，经离心后，过滤，取上清液即为中药制剂。
4.根据权利要求3所述的制备方法，其特征在于，所述步骤2)的具体过程是：
2.1)将葛根、茯苓和枳椇子混合得到混合物，按照混合物质量的10倍用量向混合物中加水，浸泡2小时，煎煮2小时，过滤，得到初级滤渣和初级滤液；
2.2)向初级滤渣中继续加水，水的加入量是三种混合物总质量的8倍，浸泡2小时，煎煮2小时，过滤，得到次级滤渣和次级滤液；
2.3)将步骤2.1)和初级滤液步骤2.2)的次级滤液混合，得到滤液。
5.根据权利要求4所述的制备方法，其特征在于，所述步骤3)中，减压浓缩的条件是：温度60℃，真空度-0.06～-0.08Mpa。
6.根据权利要求5所述的制备方法，其特征在于，所述步骤3)中，采用60％乙醇进行醇沉，醇沉时间为24小时以上。
7.根据权利要求6所述的制备方法，其特征在于，所述步骤4)中，搅拌时间为30min，搅拌速度1000r/min，离心速度3000r/min，离心时间30min。
8.一种如权利要求7所述的制备方法制备的中药制剂在制备解酒护肝药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210515120.XA CN114712424B (zh) | 2022-05-12 | 2022-05-12 | 一种具有解酒保肝作用的中药制剂及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210515120.XA CN114712424B (zh) | 2022-05-12 | 2022-05-12 | 一种具有解酒保肝作用的中药制剂及其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114712424A true CN114712424A (zh) | 2022-07-08 |
| CN114712424B CN114712424B (zh) | 2023-09-12 |
Family
ID=82231543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210515120.XA Active CN114712424B (zh) | 2022-05-12 | 2022-05-12 | 一种具有解酒保肝作用的中药制剂及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114712424B (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101507763A (zh) * | 2009-03-23 | 2009-08-19 | 丁丽华 | 一种解酒保肝药物组合物 |
| CN114404545A (zh) * | 2022-03-09 | 2022-04-29 | 四川兰冰生物药业有限公司 | 一种解酒护肝组合物及其制备方法 |
-
2022
- 2022-05-12 CN CN202210515120.XA patent/CN114712424B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101507763A (zh) * | 2009-03-23 | 2009-08-19 | 丁丽华 | 一种解酒保肝药物组合物 |
| CN114404545A (zh) * | 2022-03-09 | 2022-04-29 | 四川兰冰生物药业有限公司 | 一种解酒护肝组合物及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114712424B (zh) | 2023-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111671026A (zh) | 解酒醒酒保护胃肠道的姜黄复合解酒护肝饮及其制备方法 | |
| CN103725469B (zh) | 一种养生干红葡萄酒 | |
| US5324516A (en) | Galenic composition for decreasing blood alcohol concentration | |
| CN1625406A (zh) | 用于预防和治疗温血动物的应激状态的含有溶血磷脂酰丝氨酸的制剂 | |
| CN101284122A (zh) | 一种抗水土不服的软胶囊 | |
| CN107455625A (zh) | 一种具有抗疲劳减肥功能的植物营养素饮料及其制备工艺 | |
| CN113855735B (zh) | 一种促进代谢消化的组合物及其制备方法 | |
| CN108324921B (zh) | 一种具有祛除囊肿、保护胃粘膜功能的药物组合物及其制备方法 | |
| CN112704223A (zh) | 一种具有辅助保护胃黏膜作用的组合物及其应用、保健食品 | |
| CN101396115A (zh) | 一种低聚木糖健胃润肠口服液及其制备方法 | |
| CN114712424B (zh) | 一种具有解酒保肝作用的中药制剂及其制备方法和应用 | |
| CN114767826A (zh) | 一种醒酒护肝组合物、具有醒酒护肝功效的饮料及其制备方法 | |
| CN114651968A (zh) | 一种宿醉解酒组合物配方及其制备方法 | |
| CN107158299A (zh) | 一种具有增强学习记忆力功能的组合物及其制备方法 | |
| CN110063977B (zh) | 一种党参、沙棘复合冲剂及其应用 | |
| CN110558409A (zh) | 一种具有醒酒作用的中药养生茶及其制备方法 | |
| CN101143203A (zh) | 一种具有护肝养胃功能的复方口服液 | |
| CN109717437A (zh) | 一种解酒复合蜂蜜膏及其制备方法 | |
| CN109258976A (zh) | 一种鸡饲料中的中药添加剂 | |
| CN110755523B (zh) | 一种改善高血糖的组合物及其制备方法 | |
| CN108042595B (zh) | 一种具有保健功能的组合物及其制备方法和应用 | |
| CN113842431A (zh) | 一种具有强腰固肾、生精举阳功能的养生酒及其制备方法和应用 | |
| CN114365806A (zh) | 一种枇杷叶牛肝菌复合植物饮品及其制备方法 | |
| KR101489923B1 (ko) | 천연 생약추출물을 포함하는 숙취해소용 음료 조성물 및 이의 제조방법 | |
| TWI565469B (zh) | 有助於心血管保健之中草藥組合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |